文献速递预防保健、筛查与疫苗妇女保健

澳大利亚HPV疫苗人群初级HPV宫颈筛查头两年全国经验:观察性研究

National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
PubMed 文献 · BMJ · 2022-03-30

研究发现,25-69岁常规筛查女性中HPV16/18阳性率为2.0%,其他高危型阳性率为6.6%;HPV16/18阳性女性无论细胞学结果如何均建议转诊阴道镜,而其他高危型且细胞学阴性或低级别女性风险较低但占转诊的大多数。

要点

  • HPV16/18阳性女性宫颈癌检出率为0.98%,即使细胞学阴性也为0.32%,应直接转诊阴道镜。
  • 其他高危型且细胞学阴性或低级别女性CIN3+风险3.4%、癌症0.02%,可安全采用两轮HPV复查。
  • 疫苗高覆盖的25-34岁女性HPV16/18阳性率仅2.2%,HPV16/18驱动的转诊比例低。

核心结论

  • 阴道镜转诊阈值应考虑潜在癌症风险,HPV16/18阳性女性在首轮筛查中无论细胞学结果如何均属高风险。
  • 其他高危型且细胞学阴性或低级别女性严重病变风险低,但占该筛查算法转诊的62.0%,可安全采用两轮HPV复查而非一轮。

研究设计与样本

  • 多数40岁以下女性既往已接种HPV16/18疫苗。

主要发现

  • 25-69岁阴道镜转诊率3.5%,计入尚未进行12个月复查的女性后估计为6.2%。

关键数值与推荐

  • 初级HPV筛查,HPV16/18阳性即转诊阴道镜。
  • 其他高危型阳性者采用液基细胞学分流,阈值非典型鳞状细胞-不能排除高级别鳞状上皮内病变。
  • 分流后细胞学阴性或低级别者建议12个月后HPV复查,复查时任何高危型阳性即转诊。

临床怎么用

  • 对HPV16/18阳性女性,无论细胞学结果如何均应直接转诊阴道镜。
  • 对其他高危型且细胞学阴性或低级别女性,可考虑两轮HPV复查而非一轮,以安全减少阴道镜转诊。
  • 在HPV疫苗高覆盖年轻女性中,HPV16/18相关转诊负担较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review the first two years of the primary human papillomavirus (HPV) cervical screening programme in an HPV vaccinated population. DESIGN: Observational study. SETTING: Australia. PARTICIPANTS: 3 745 318 women with a primary HPV test between 1 December 2017 and 31 December 2019; most women aged <40 years had previously been offered vaccination against HPV16 and HPV18. INTERVENTIONS: Primary HPV screening with referral if HPV16 or HPV18 (HPV16/18) positive and triage with liquid based cytology testing (threshold atypical squamous cells-cannot exclude high grade squamous intraepithelial lesion) for women who were positive for high risk HPV types other than 16/18. A 12 month follow-up HPV test was recommended in triaged women with a negative or low grade cytology result, with referral if they tested positive for any high risk HPV type at follow-up. MAIN OUTCOME MEASURES: Proportion of women who had attended for their first HPV screening test, tested positive, and were referred for colposcopy; and short term risk of detecting cervical intraepithelial neoplasia (CIN) grade 2 or worse, CIN grade 3 or worse, or cancer. RESULTS: 54.6% (n=3 507 281) of an estimated 6 428 677 eligible women aged 25-69 had undergone their first HPV test by the end of 2019. Among those attending for routine screening, positivity for HPV16/18 and for HPV types not 16/18 was, respectively, 2.0% and 6.6% in women aged 25-69 (n=3 045 844) and 2.2% and 13.3% in highly vaccinated cohorts of women aged 25-34 (n=768 362). Colposcopy referral (ages 25-69 years) was 3.5%, increasing to an estimated 6.2% after accounting for women who had not yet had a 12 month repeat test. Cervical cancer was detected in 0.98% (456/46 330) of women positive for HPV16/18 at baseline, including 0.32% (89/28 003) of women with HPV16/18 and negative cytology. Women with HPV types not 16/18 and negative or low grade cytology at both baseline and 12 months were at low risk of serious disease (3.4% CIN grade 3 or worse; 0.02% cancer; n=20 019) but estimated to account for 62.0% of referrals for this screening algorithm. CONCLUSIONS: Colposcopy referral thresholds need to consider underlying cancer risk; on this basis, women with HPV16/18 in the first round of HPV screening were found to be at higher risk regardless of cytology result, even in a previously well screened population. Women with HPV types not 16/18 and negative or low grade cytology showed a low risk of serious abnormalities but constitute most referrals and could be managed safely with two rounds of repeat HPV testing rather than one. HPV16/18 driven referrals were low in HPV vaccinated cohorts.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Smith MA, Sherrah M, Sultana F, et al. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. BMJ. 2022. PMID: 35354610. doi:10.1136/bmj-2021-068582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。